Diadexus (VXGN) 10-Q 5 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 31, 2014
Document And Entity Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'DDXS	'
Entity Registrant Name	'diaDexus, Inc.	'
Entity Central Index Key	'0001036968	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	55,153,376

Condensed_Balance_Sheets

Condensed Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$10,416	$16,847
Accounts receivable, net of reserve of $7 and $5 at June 30, 2014 and December 31, 2013, respectively	4,433	3,027
Inventories	353	460
Prepaid expenses and other current assets	912	845
Total current assets	16,114	21,179
Restricted cash	1,400	1,400
Property and equipment, net	842	968
Other long-term assets	65	100
Total assets	18,421	23,647
Current liabilities:	'	'
Accounts payable	809	611
Notes payable, current portion	2,778	2,763
Deferred revenues, current portion	109	228
Deferred rent, current portion	89	51
Unfavorable lease obligations	757	697
Accrued and other current liabilities	2,666	2,203
Total current liabilities	7,208	6,553
Non-current portion of notes payable	5,654	7,047
Non-current portion of deferred rent	272	336
Non-current portion of unfavorable lease obligation	1,378	1,777
Other long term liabilities	477	414
Total liabilities	14,989	16,127
Commitments and contingencies (Note 13)	'	'
Stockholders' equity:	'	'
Preferred Stock, $0.01 par value, 19,979,500 shares authorized; none issued and outstanding	'	'
Common stock, $0.01 par value; 100,000,000 shares authorized; 55,062,516 and 54,751,685 shares issued and outstanding at June 30, 2014 and December 31, 2013, respectively	551	548
Additional paid-in capital	207,318	206,868
Accumulated deficit	-204,437	-199,896
Total stockholders' equity	3,432	7,520
Total liabilities and stockholders' equity	$18,421	$23,647

Condensed_Balance_Sheets_Paren

Condensed Balance Sheets (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Accounts receivable, reserve	$7	$5
Preferred Stock, par value	$0.01	$0.01
Preferred Stock, shares authorized	19,979,500	19,979,500
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	55,062,516	54,751,685
Common stock, shares outstanding	55,062,516	54,751,685

Condensed_Statements_of_Compre

Condensed Statements of Comprehensive Loss (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenues:	'	'	'	'
Product sales	$6,566	$6,141	$11,577	$11,601
Service revenue	1,035	'	1,384	'
License revenue	75	77	150	153
Royalty revenue	'	'	'	18
Total revenues	7,676	6,218	13,111	11,772
Operating costs and expenses:	'	'	'	'
Product costs	1,810	1,890	3,403	3,715
Service costs	142	'	187	'
Sales and marketing	2,648	1,972	5,129	3,922
Research and development	1,247	1,147	4,288	2,263
General and administrative	2,078	1,667	4,221	3,647
Total operating costs and expenses	7,925	6,676	17,228	13,547
Loss from operations	-249	-458	-4,117	-1,775
Interest income, interest expense and other income (expense), net:	'	'	'	'
Interest income	'	'	1	2
Interest expense	-205	-92	-424	-185
Other income (expense), net	13	104	11	347
Loss before income tax	-441	-446	-4,529	-1,611
Income tax	'	'	-12	-5
Net loss	-441	-446	-4,541	-1,616
Basic and diluted net loss per share:	($0.01)	($0.01)	($0.08)	($0.03)
Weighted average shares used in computing basic and diluted net loss per share	54,938,028	54,206,637	54,855,369	54,055,972
Comprehensive loss:	'	'	'	'
Net loss	-441	-446	-4,541	-1,616
Comprehensive loss	($441)	($446)	($4,541)	($1,616)

Condensed_Statements_of_Cash_F

Condensed Statements of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Operating activities:	'	'
Net loss	($4,541)	($1,616)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Loss (gain) on disposal of property and equipment and assets held for sale	-5	-347
Depreciation and amortization	280	266
Stock-based compensation	351	239
Provision for rebate reserve	-5	123
Provision for doubtful account	7	5
Noncash other interest expense	17	15
Noncash interest associated with notes payable	122	48
Unfavorable lease	-339	-287
Changes in operating assets and liabilities	'	'
Accounts receivable	-1,408	36
Inventory	107	-100
Prepaid expenses, other current assets and other long-term assets	-58	152
Accounts payable	169	10
Accrued liabilities and other long term liabilities	478	-142
Deferred rent	-26	12
Deferred revenue	-119	-158
Net cash used in operating activities	-4,970	-1,744
Investing activities:	'	'
Purchases of property and equipment	-139	-128
Maturities of available-for-sale investments	'	747
Proceeds from sale of assets and equipment	4	225
Net cash provided by (used in) investing activities	-135	844
Financing activities:	'	'
Principal repayment of notes payable	-1,428	'
Proceeds from issuance of common stock	102	19
Net cash provided by (used in) financing activities	-1,326	19
Net decrease in cash and cash equivalents	-6,431	-881
Cash and cash equivalents, beginning of period	16,847	12,851
Cash and cash equivalents, end of period	10,416	11,970
Supplemental disclosure:	'	'
Cash paid for interest	303	131
Disposal of assets held for sales in prepaid expenses and other current assets	'	442
Net change in acquisition of property and equipment in accounts payable	29	-48
Net change in accrued liabilities from acquisition of property and equipment	($10)	($19)

Business_Overview

Business Overview	6 Months Ended
	Jun. 30, 2014
Business Overview	'
	1. Business Overview
	Formation of the Company
	diaDexus, Inc., a Delaware corporation (the “Company”), is a life sciences company focused on developing and commercializing proprietary diagnostic products addressing unmet needs in cardiovascular disease (“CVD”). The Company sells its diagnostic products to laboratories. Physicians order testing for their patients from these laboratories and use the results to aid in assessing their patients risk for CVD.
	The Company’s products, PLAC® Tests, are designed to provide information, over and above traditional risk factors, to help identify individuals at increased risk of suffering a heart attack or stroke. Some of these events may be reduced with earlier risk detection and more aggressive risk-reducing strategies, including treatment to lower LDL-cholesterol goals with statins. The Company has commercialized two PLAC Tests. One test, the PLAC Test ELISA Kit (the “PLAC ELISA Test”), measures the mass of circulating Lp-PLA2 in the blood. The PLAC ELISA Test is the only Lp-PLA2 blood test cleared by the US Food and Drug Administration (the “FDA”) to aid in assessing risk for both coronary heart disease and ischemic stroke associated with atherosclerosis. The second test, the PLAC Test for Lp-PLA2 Activity (the “PLAC Activity Test”), is an enzyme assay for the quantitative determination of Lp-PLA2 activity levels in human plasma and serum on automated clinical chemistry analyzers, to be used in conjunction with clinical evaluation and patient risk assessment as an indicator of atherosclerotic cardiovascular disease. The Company is currently commercializing the PLAC ELISA Test primarily in the United States and Europe and the PLAC Activity Test primarily in Europe.
	The Company has incurred substantial losses since its inception, and expects to continue to incur net losses for at least the next few years. To date, the Company has funded its operations primarily through private placements of preferred stock and debt financing, as well as through revenue generated from the sale of products and service.
	In September 2011, the Company entered into a Loan and Security Agreement with Comerica Bank, which was amended in September 2012 and again in October 2013 (see Note 8 of these Notes to Condensed Financial Statements). The Loan and Security Agreement contains various covenants. If the Company breaches any of these covenants or is unable to make a required payment of principal or interest, or experiences a material adverse change to its business, it could result in a default under the loan. Additionally, the Company is required to (i) maintain a liquidity ratio of not less than 1.25 to 1 and (ii) ensure its cumulative net loss does not exceed $6 million beginning July 1, 2013 in accordance with GAAP, and failure to do so could result in a default under the loan. The cumulative net loss under this covenant was $5.1 million as of June 30, 2014. A material failure or breach or termination of any of the Company’s agreements in the Lp-PLA2 product supply chain may also result in an event of default. Upon the occurrence of an event of default under the loan, the lender could elect to declare all amounts outstanding to be immediately due and payable. If the Company is unable to repay those amounts, the lender could proceed against the collateral granted to them to secure such indebtedness. The Company has pledged substantially all of its assets, other than its intellectual property, as collateral under the loan.
	The Company’s future liquidity requirements may increase beyond currently expected levels if it fails to maintain compliance with the loan covenants. In order to meet the future liquidity needs, the Company may become reliant on additional equity and/or debt financing. Additional funding may not be available when needed or on terms acceptable to the Company. Any additional equity financing may be dilutive to stockholders, and debt financing, if available, may involve restrictive covenants. The Company cannot assure you that it will be able to raise any such additional funding or, if available, that such funding would be on favorable terms.
	PLAC Test ELISA Kit
	The Company introduced its initial PLAC ELISA Test in 2004 which uses immunoassay microtiter plate technologies to measure levels of Lp-PLA2. The infrastructure for performing microtiter plate tests typically exists only at large and midsize clinical reference laboratories and large hospitals, which must be certified by the US Department of Health and Human Services (“DHHS”) for high-complexity diagnostics under the Clinical Laboratory Improvement Amendments (“CLIA”). Smaller hospitals and clinics can order the PLAC ELISA Test for their patients from those institutions that are able to perform this test and offer the PLAC ELISA Test. Patients can have their blood drawn at a local laboratory and shipped to the more advanced institutions for analysis. The Company markets the PLAC ELISA Test in the United States, Europe, Israel and Mexico.
	PLAC Test for Lp-PLA2 Activity
	The Company introduced the PLAC Activity Test in Europe in March 2012. The PLAC Activity Test is an enzyme assay for the quantitative determination of Lp-PLA2 activity levels in human serum or plasma. The PLAC Activity Test uses automated clinical chemistry technology which is more prevalent than the microplate technology used for the PLAC ELISA Test. As such, a broader array of institutions can conduct the PLAC Activity Test. This group includes clinical laboratories and hospitals of all sizes and physician operated laboratories (“POLs”). In addition, the sample handling requirements are much less stringent for the PLAC Activity Test compared to the PLAC ELISA Test, allowing greater ease of use for those facilities processing specimens. The PLAC Activity Test is currently available in Europe for use in conjunction with clinical evaluation and patient risk assessment as an indicator of atherosclerotic cardiovascular disease. The Company affixed the CE marking for this intended use by self-certification in January 2012. The PLAC Activity Test is available on a commercial basis only in Europe. The Company is pursuing 510(k) clearance for this test from the FDA to commercialize this assay format in the United States.
	The Company had a pre-submission meeting with the FDA in September 2013, which resulted in the Company advancing its clinical program to support the submission of the PLAC Activity Test to the FDA. The Company then partnered with a large longitudinal cardiovascular disease study, Reasons for Geographic and Racial Differences in Stroke (“REGARDS”), to validate the PLAC Activity Test. The Company completed the clinical study sample validation in the first quarter of 2014 and submitted a 510(k) application to the FDA in June 2014, which was accepted for substantive review in July 2014.
	Pipeline
	There are several published clinical studies that provide preliminary evidence that Lp-PLA2 levels may have clinical utility in diseases or indications other than those for which the Company’s PLAC Tests are currently cleared. The Company intends to explore these other indications, while focusing on cardiovascular disease risks, such as risks of secondary cardiac events and risks of cardiac events in the context of other diseases.
	In March 2014, the Company entered into an agreement to license the rights to develop and commercialize three independent biomarkers to aid in risk prediction and prognosis for heart failure. They are: MR-proADM (midregional pro adrenomedullin), MR-proANP (midregional pro atrial natriuretic peptide), and CT-proET1 (C-terminal pro endothelin-1). The Company plans to develop three individual diagnostics tests, one per biomarker, which will address different stages of heart failure from diagnosis to survival. The Company commenced feasibility studies for MR-proADM and MR-proANP in March 2014. The Company estimates that the addressable United States market for these tests is similar to that of its PLAC Tests, approximately 36 million lives in 2012.
	The Company is also interested in acquiring biomarkers or rights to biomarkers that could be measured at our existing partner cardiovascular specialty laboratories. The Company is specifically interested in assets that would have a development period of three years or less and would help uncover other cardiovascular disease risks.
	Basis of Presentation
	The accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. In the opinion of management, the accompanying unaudited condensed financial statements have been prepared on a consistent basis with the December 31, 2013 audited financial statements and include all adjustments, consisting of normal recurring adjustments, that are necessary to fairly state the Company’s financial position as of June 30, 2014, results of operations for both the three and six months ended June 30, 2014 and 2013 and cash flows for the six months ended June 30, 2014 and 2013. Starting in January 2013, the Company includes excise tax collected from customer product sales. The Company recognized $98,000 and $110,000 in charged excise tax within product revenue and product costs, respectively, for the three months ended June 30, 2014, and $109,000 and $132,000, respectively, for the same periods in 2013. The Company recognized $171,000 and $193,000 in charged excise tax within product revenue and product costs, respectively, for the six months ended June 30, 2014 and $214,000 and $253,000, respectively, for the same periods in 2013.
	All references in these notes to financial statements to the “Company,” “we,” “us” and “our” refer to diaDexus, Inc. (f/k/a VaxGen, Inc.), a Delaware corporation, unless the context requires otherwise.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Summary of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies
	The Company’s significant accounting policies are disclosed in the Company’s annual report on Form 10-K for the year ended December 31, 2013, filed with the Securities and Exchange Commission (“SEC”) on March 11, 2014, and have not changed as of June 30, 2014.
	Recent Accounting Pronouncements
	In July 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2013-11, “Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force).” The amendments in this ASU provide guidance on the financial statements presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability. The amendments in this ASU do not require new recurring disclosures and are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. This ASU has been adopted since the effective date and there was no impact to the financial statements as a result of this adoption.
	In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers” The amendment in this ASU provide guidance on the revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The core principle of this update provides guidance to identify the performance obligations under the contract(s) with a customer and how to allocate the transaction price to the performance obligations in the contract. It further provide guidance to recognize revenue when (or as) the entity satisfies a performance obligation. The Company is evaluating the impact of this standard.

Cash_and_Cash_Equivalents

Cash and Cash Equivalents	6 Months Ended
	Jun. 30, 2014
Cash and Cash Equivalents	'
	3. Cash and Cash Equivalents
	The Company maintains its cash in bank accounts, which at times may exceed federally insured limits. The Company has not experienced any losses on such accounts. The Company considers all highly liquid investments purchased with an original maturity of three months or less at the time of purchase to be cash equivalents.
	The following is a summary of cash and cash equivalents at June 30, 2014 and December 31, 2013 (in thousands):
		30-Jun-14
				Unrealized		Unrealized		Estimated
		Cost Basis		Gains		Losses		Fair Value
	Cash and cash equivalents:
	Cash	$	6,369	$	—	$	—	$	6,369
	Money market funds		4,047		—		—		4,047
	Total cash and cash equivalents	$	10,416	$	—	$	—	$	10,416
		31-Dec-13
				Unrealized		Unrealized		Estimated
		Cost Basis		Gains		Losses		Fair Value
	Cash and cash equivalents:
	Cash	$	12,800	$	—	$	—	$	12,800
	Money market funds		4,047		—		—		4,047
	Total cash and cash equivalents	$	16,847	$	—	$	—	$	16,847
	Fair Value Measurements
	In accordance with FASB’s Accounting Standard Codification (“ASC”) 820, the Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The guidance establishes three levels of the fair value hierarchy as follows:
	Level 1: Observable inputs, such as quoted prices in active markets for identical assets or liabilities;
	Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;
	Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The following table represents the Company’s fair value hierarchy for its financial assets (cash and cash equivalents) measured at fair value on a recurring basis as of June 30, 2014 and December 31, 2013 (in thousands):
				Fair Value Measurements
				Quoted Prices		Significant
				In Active		other		Significant
		Balance at		Markets for		Observable		Unobservable
		June 30,		Identical Assets		Inputs		Inputs
		2014		Level 1		Level 2		Level 3
	Assets:
	Cash	$	6,369	$	6,369	$	—	$	—
	Money market funds		4,047		4,047		—		—
	Restricted cash		1,400		—		1,400		—
		$	11,816	$	10,416	$	1,400	$	—
				Fair Value Measurements
				Quoted Prices		Significant
				In Active		other		Significant
		Balance at		Markets for		Observable		Unobservable
		December 31,		Identical Assets		Inputs		Inputs
		2013		Level 1		Level 2		Level 3
	Assets:
	Cash	$	12,800	$	12,800	$	—	$	—
	Money market funds		4,047		4,047		—		—
	Restricted cash		1,400		—		1,400		—
		$	18,247	$	16,847	$	1,400	$	—
	The fair value of the notes payable is valued based on Level 2 inputs and approximates its book value. The fair value of the notes payable is based on the present value of expected future cash flows and assumptions about current interest rates and the credit worthiness of the Company. As of June 30, 2014, the notes payable is carried at face value of $8.6 million less any unamortized debt discount.
	The carrying value of other financial instruments, including cash, accounts receivable, accounts payable and other payables, approximates fair value due to their short maturities.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2014
Inventory	'
	4. Inventory
	Inventory consists of the following (in thousands):
		June 30,			December 31,
		2014			2013
	Finished goods	$	219	$	361
	Raw materials		134		99
		$	353	$	460

Property_Plant_and_Equipment

Property, Plant and Equipment	6 Months Ended
	Jun. 30, 2014
Property, Plant and Equipment	'
	5. Property, Plant and Equipment
	Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized, and maintenance and repairs are charged to expense as incurred. When property and equipment are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses other depreciation methods for tax purposes where appropriate. The estimated useful lives for significant property and equipment categories are as follows:
	Office and laboratory equipment	3 years
	Computer equipment and software	3 years
	Leasehold improvements	Term of lease agreement
	The following is a summary of property and equipment at cost less accumulated depreciation as of June 30, 2014 and December 31, 2013 (in thousands):
		June 30,			December 31,
		2014			2013
	Laboratory equipment	$	2,403		$	2,299
	Leasehold improvements		616			616
	Computer and software		332			299
	Furniture and fixtures		81			81
	Construction in progress		48			149
			3,480			3,444
	Less: Accumulated depreciation and amortization		(2,638	)		(2,476	)
		$	842		$	968
	Depreciation and amortization expense was $141,000 and $280,000 for the three and six months ended June 30, 2014, respectively, and $136,000 and $266,000, respectively, for the same periods in 2013.

Total_Accrued_and_Other_Curren

Total Accrued and Other Current Liabilities	6 Months Ended
	Jun. 30, 2014
Total Accrued and Other Current Liabilities	'
	6. Total Accrued and Other Current Liabilities
	Total accrued and other current liabilities include the following as of June 30, 2014 and December 31, 2013 (in thousands):
		June 30,		December 31,
		2014		2013
	Accrued payroll and related expense	$	1,067	$	1,481
	Accrued research obligations		817		46
	Accrued consulting expense		174		207
	Accrued inventory		125		—
	Accrued travel and entertainment		88		53
	Accrued sales and excise tax		73		71
	Accrued legal and patent expense		67		124
	Accrued royalty expense		65		65
	Accrued property and equipment		—		11
	Other current liabilities		190		145
	Total accrued and other current liabilities	$	2,666	$	2,203
	Accrued research obligations represent approximately $0.7 million in payments payable to B.R.A.H.M.S. GmbH, for the license of three heart failure markers. This balance will be settled in March 2015.

Concentration_of_Credit_Risk

Concentration of Credit Risk	6 Months Ended
	Jun. 30, 2014
Concentration of Credit Risk	'
	7. Concentration of Credit Risk
	Revenues from the following customers represented a significant portion of total revenue for the three and six months ended June 30, 2014 and 2013 and accounts receivable as of June 30, 2014 and December 31, 2013:
		Revenue						Revenue						Accounts Receivable
		Three Months Ended						Six Months Ended
		June 30,						June 30,						June 30,			December 31,
		2014			2013			2014			2013			2014			2013
	Customer A		34	%		41	%		32	%		44	%		28	%		36	%
	Customer B		15	%		14	%		15	%		13	%		15	%		11	%
	Customer C		13	%		5	%		11	%		4	%		24	%		3	%
	Customer D		13	%		9	%		14	%		9	%		7	%		10	%
	Customer E		5	%		6	%		4	%		6	%		6	%		15	%
	Total		80	%		75	%		76	%		76	%		80	%		75	%

Notes_Payable

Notes Payable	6 Months Ended
	Jun. 30, 2014
Notes Payable	'
	8. Notes Payable
	In September 2011, the Company entered into a Loan and Security Agreement with Comerica Bank (“Comerica”) to borrow up to $5 million, the entire amount of which was borrowed at a rate of 5.25% per annum (the “Original Term Loan”). Prior to the amendments described below, the Original Term Loan was payable in 36 monthly installments which were to begin in October 2012, with interest only payments being made from October 2011 to September 2012. The Company paid an initial fee of $25,000 for access to this loan and will be required to pay an additional fee of $100,000 following repayment of the loan. The Company may prepay all, but not less than all, of the loaned amount with 30 days advance notice to Comerica. In connection with the loan, the Company issued a warrant to Comerica to purchase 480,769 shares of the Company’s common stock (see Note 12 of these Notes to Condensed Financial Statements).
	The term loan is secured by a first priority security interest on all of the Company’s assets excluding the Company’s intellectual property (except for rights to payment related to the sale, licensing or disposition of such intellectual property rights) and property not assignable without consent by a third party or with respect to which granting a security interest is contrary to law. In addition, the Company has agreed not to sell, assign, transfer, pledge or otherwise encumber its intellectual property to another entity without Comerica’s approval or consent, subject to certain exceptions.
	The Loan and Security Agreement contains customary representations and warranties, covenants, events of defaults and termination provisions. The affirmative covenants include, among other things, that the Company timely file taxes, maintain good standing and government compliance, maintain a liquidity ratio of not less than 1.25 to 1, ensure its cumulative net loss does not exceed $6 million beginning July 1, 2013 in accordance with GAAP, maintain primary depository and operating accounts with Comerica, maintain liability and other insurance, and provide security interests to Comerica in the collateral of any subsidiary formed or acquired by the Company in the future. The negative covenants provide, among other things, that without the prior consent of Comerica, the Company may not dispose of certain assets, engage in certain business combinations or acquisitions, incur additional indebtedness or encumber any of the Company’s property (subject to certain exceptions), pay dividends on the Company’s capital stock or make prohibited investments. The Loan and Security Agreement provides that an event of default will occur if, among other triggers, (1) the Company defaults in the payment of any amount payable under the agreement when due, (2) there occurs any circumstance or circumstances that could reasonably be expected to result in a material adverse effect on the Company’s business, operations or condition, or on the Company’s ability to perform its obligations under the agreement, (3) the Company becomes insolvent, (4) the Company undergoes a change in control or (5) the Company breaches any negative covenants or certain affirmative covenants in the agreement or, subject to a cure period, otherwise neglects to perform or observe any material item in the agreement. A material failure or breach or termination of any of the Company’s agreement in the Lp-PLA2 product supply chain may also result in an event of default. The repayment of the term loan may be accelerated, at the option of Comerica, following the occurrence of an event of default, which would require the Company to pay to Comerica an amount equal to the sum of: (i) all outstanding principal plus accrued interest, (ii) the final payment, plus (iii) all other sums, that shall have become due and payable but have not been paid, including interest at the default rate with respect to any past due amounts. As of June 30, 2014, the Company was in compliance with all the covenants including having a cumulative net loss of $5.1 million as of June 30, 2014.
	On September 11, 2012, the Company and Comerica entered into an Amended and Restated Loan and Security Agreement (the “First Amended Loan and Security Agreement”). The First Amended Loan and Security Agreement extended the interest-only payment period for an additional twelve months, through September 23, 2013, and extended the maturity date for an additional twelve months, to September 23, 2016. The First Amended Loan and Security Agreement also reduced the monthly principal payments by amortizing the loan over a 48 month basis, resulting in an increased balloon payment of principal on the maturity date. The Company paid a fee of $50,000 for access to the First Amended Loan and Security Agreement. Pursuant to the First Amended Loan and Security Agreement, the Company also issued a warrant to Comerica to purchase 168,919 shares of its common stock. The warrant has an exercise price of $0.37 per share and will expire on September 11, 2019 (see Note 12 of these Notes to Condensed Financial Statements).
	The Company accounted for this amendment as a debt modification since the terms of the original Loan and Security Agreement and the First Amended Loan and Security Agreements were not substantially different, and the present value of cash flows of the modified instrument was within 10% of the cash flows of the original debt instrument. Accordingly, debt discount of $48,000 associated with the First Amended Loan and Security Agreement, and unamortized debt discount of $72,000 from the Original Term Loan, is amortized as an adjustment of interest expense over the term of the First Amended Loan and Security Agreement using the effective interest method.
	In October 2013, the Company and Comerica entered into a Second Amended and Restated Loan and Security Agreement (the “Second Amended Loan and Security Agreement”). The Second Amended Loan and Security Agreement increased the aggregate principal amount of the loan by $5 million, the entire amount of which was borrowed on October 17, 2013, for a total outstanding principal amount of $10 million, with interest at a fixed per annum rate equal to 6.45%. The Second Amended Loan and Security Agreement also extended the interest-only payment period for an additional three months, through December 31, 2013, and extended the maturity date for an additional three months, to December 1, 2016. The Second Amended Loan and Security Agreement also reduced the monthly principal payments by amortizing the loan over a 42 month basis, resulting in an increased balloon payment of principal on the maturity date. The Company paid a fee of $50,000 with respect to the Second Amended Loan and Security Agreement. Pursuant to the Second Amended Loan and Security Agreement, the Company also issued a warrant to Comerica to purchase 96,685 shares of its common stock. The warrant has an exercise price of $1.81 per share and will expire on October 17, 2020 (See Note 12 of these Notes to Condensed Financial Statements).
	The Company accounted for this Second Amended Loan and Security Agreement as a debt modification since the terms of the original and the amended Loan and Security Agreements were not substantially different.
	The Company recorded debt discount of $136,000 associated with the Second Amended Loan and Security Agreement, and unamortized debt discount of $77,000 from the Original and First Amended Term Loan will be amortized as an adjustment of interest expense over the term of the Second Amended Loan and Security Agreement using the effective interest method.
	As of June 30, 2014, future minimum payments for the notes payable are as follows (in thousands):
	2014 (remainder of year)	$	1,686
	2015		3,233
	2016		4,728
	Total minimum payments		9,647
	Less: Amount representing interest		(1,075	)
	Present value of minimum payments		8,572
	Less: Unamortized debt discount		(140	)
	Notes payable, net		8,432
	Less: Notes payable, current portion		2,778
	Non-current portion of notes payable	$	5,654

Common_Stock

Common Stock	6 Months Ended
	Jun. 30, 2014
Common Stock	'
	9. Common Stock
	Pursuant to the Company’s restated certificate of incorporation, as amended, the Company is authorized shares of its common stock, par value of $0.01 per share, to 100,000,000. The holders of common stock are entitled to receive dividends, as, when and if declared by the Company’s Board of Directors out of funds legally available for distribution, subject to the restriction on dividends contained in the Company’s Second Amended Loan and Security Agreement with Comerica (see Note 8 to these Notes to Condensed Financial Statements).

Basic_and_Diluted_Net_Loss_per

Basic and Diluted Net Loss per Share	6 Months Ended
	Jun. 30, 2014
Basic and Diluted Net Loss per Share	'
	10. Basic and Diluted Net Loss per Share
	Basic net loss per common share is based on the weighted average number of common shares outstanding during the period. Diluted net loss per common share is based on the weighted average number of common shares and other dilutive securities outstanding during the period, provided that including these dilutive securities does not increase the net loss per share.
	The effect of the options and warrants was anti-dilutive for the six months ended June 30, 2014 and 2013. The following table shows the total outstanding securities considered anti-dilutive and therefore, excluded from the computation of diluted net loss per share (in thousands):
		As of
		June 30,
		2014		2013
	Options to purchase common stock		9,955		9,078
	Warrants to purchase common stock		266		650
	Restricted stock units		42		—
	Total		10,263		9,728

Stock_Based_Compensation

Stock Based Compensation	6 Months Ended
	Jun. 30, 2014
Stock Based Compensation	'
	11. Stock Based Compensation
	Stock Option Plans
	2012 Equity Incentive Award Plan
	The Company’s stockholders approved the 2012 Equity Incentive Award Plan (the “2012 Plan”) at the 2012 Annual Meeting of Stockholders on May 17, 2012 and approved 3,000,000 shares of common stock authorized for issuance. Upon approval of the 2012 Plan, all shares of common stock that remained available for issuance under the 1996 Stock Option Plan (the “1996 Plan”) and the 1998 Director Stock Option Plan (the “Director Plan”) were added to the shares reserved under the 2012 Plan. In addition, pursuant to the 2012 Plan, any shares of common stock subject to awards previously granted under the 1996 Plan, the Director Plan and certain non-plan option agreements entered into with certain individuals as of March 31, 2012 that terminate, expire or lapse will become available for issuance under the 2012 Plan. The 2012 Plan was amended on May 29, 2014 upon stockholder approval of an amendment to the 2012 Plan at the 2014 Annual Meeting of Stockholders to increase the number of shares reserved for issuance thereunder by 4,000,000 shares. The 2012 Plan provides for the granting of options, restricted stock awards, restricted stock unit awards (“RSU”), performance awards, dividend equivalents awards, deferred stock awards, deferred stock unit awards, stock payment awards and stock appreciation rights to employees, non-employee directors and consultants. The Company has granted options and RSUs under the 2012 Plan. Options granted under the 2012 Plan may be designated as qualified or nonqualified at the discretion of the Compensation Committee of the Board of Directors. Generally, shares issuable upon exercise of options vest ratably over four years, beginning one year from the date of grant; however, options can vest upon grant. Option terms expire no later than 10 years from the date of grant, or 5 years from the date the option is granted to a greater than 10% stockholder. The stock options are exercisable at not less than the fair market value of the stock at the date of grant, or not less than 110% of the fair market value of the stock at the date of grant if granted to a greater than 10% stockholder. RSU granted under the 2012 Plan entitle the recipient to receive one share of the Company’s common stock for every RSU upon vesting. RSUs vest annually. As of June 30, 2014, options to purchase 3,477,674 shares of common stock were outstanding, 41,708 shares of common stock were issuable upon the settlement of outstanding RSUs and 5,784,701 shares were available for issuance under the 2012 Plan.
	1996 Stock Option Plan
	The 1996 Plan initially had 4,750,000 shares of common stock authorized for issuance and a provision that automatically increased this number by 3.5% of the issued and outstanding common stock on the last trading day of the December immediately preceding each fiscal year through January 2007. Options granted under the 1996 Plan were designated as qualified or nonqualified at the discretion of the Compensation Committee of the Board of Directors. Generally, shares issuable upon exercise of options vest ratably over four years, beginning one year from the date of grant; however, options could vest upon grant. All options expire no later than 10 years from the date of grant. Qualified stock options are exercisable at not less than the fair market value of the stock at the date of grant, and nonqualified stock options are exercisable at prices determined at the discretion of the Board of Directors, but not less than 85% of the fair market value of the stock at the date of grant. On May 17, 2012, the 1996 Plan was terminated in connection with the effectiveness of the 2012 Plan. All 1,555,492 shares that were available for issuance under the 1996 Plan were transferred to the 2012 Plan, and the 6,398,904 shares that were subject to awards outstanding under the 1996 Plan remained outstanding pursuant to the terms of the 1996 Plan. As of June 30, 2014, options to purchase 2,843,685 shares of common stock were outstanding pursuant to the terms of the 1996 Plan.
	1998 Director Stock Option Plan
	The Director Plan for non-employee directors initially had 300,000 shares of common stock authorized for issuance. On May 17, 2012, the Director Plan was terminated in connection with the effectiveness of the 2012 Plan. All 130,000 shares that were available for issuance under the Director Plan were transferred to the 2012 Plan, and the 170,000 shares that were subject to awards outstanding under the Director Plan remained outstanding pursuant to the terms of the Director Plan. As of June 30, 2014, no options were outstanding pursuant to the terms of the Director Plan.
	Non-Plan Grants
	In October 2004, the Company granted non-qualified stock options to purchase 30,000 shares of common stock outside of the Company’s stock option plans to its former director with an exercise price of $12.27 per share. These options were granted with terms that are substantially in accordance with the Company’s standard stock option terms. As of June 30, 2014, all of these options remained outstanding.
	In September 2011, the Company granted non-qualified stock options to purchase 1,530,000 shares of common stock outside of the Company’s stock option plans to its current Chief Executive Officer with an exercise price of $0.25 per share. These options were granted with terms that are substantially in accordance with the Company’s standard stock option terms. As of June 30, 2014, all of these options remained outstanding.
	In October 2011, the Company granted non-qualified stock options to purchase 1,130,000 shares of common stock outside of the Company’s stock option plans to its current Chief Business Officer with an exercise price of $0.26 per share. These options were granted with terms that are substantially in accordance with the Company’s standard stock option terms. As of June 30, 2014, 1,018,458 of these options remained outstanding.
	On February 1, 2012, the Company granted non-qualified stock options to purchase 1,060,000 shares of common stock outside of the Company’s stock option plans to its current Chief Financial Officer with an exercise price of $0.28 per share. These options were granted with terms that are substantially in accordance with the Company’s standard stock option terms. As of June 30, 2014, 1,055,352 of these options remained outstanding.
	Restricted Stock Units
	On August 6, 2013, the Company awarded an aggregate of 41,708 RSUs to its directors with a grant-date fair value equal to approximately $55,000 in the aggregate. Each RSU entitles the recipient to receive one share of the Company’s common stock upon vesting. The RSUs awarded to directors vest annually. The fair value of nonvested RSUs is based on the Company’s closing stock price on the date of grant. As of June 30, 2014, all of these RSUs remained outstanding and none was vested. A summary for the six months ended June 30, 2014 is as follows:
								Weighted
					Average			Remaining
					Grant Date			Vesting			Aggregate
		Shares of			Fair Value			Period			Intrinsic
		Underlying RSUs			Per Share			(In years)			Value
	Nonvested at December 31, 2013		41,708		$	1.33
	Options exercised		—			—
	Options cancelled/forfeited/expired		—			—
	Nonvested at June 30, 2014		41,708		$	1.33			—		$	30,864
	The following table summarizes stock compensation expense related to employee stock options and employee stock-based compensation for the three and six months ended June 30, 2014 and 2013, which was incurred as follows (in thousands):
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Stock-based compensation expense:
	General and administrative	$	139		$	57		$	263		$	117
	Research and development		(30	)		30			13			54
	Sales and marketing		31			32			63			58
	Product costs		7			6			12			10
	Total stock-based compensation expense	$	147		$	125		$	351		$	239
	Stock-based compensation expense recognized during the three and six months ended June 30, 2014 and 2013 includes compensation expense for stock-based awards granted to employees based on the grant date fair value estimated in accordance with the provisions of ASC 718. As of June 30, 2014, the total remaining unrecognized cost was approximately $979,000 to be recognized over approximately two years.
	Valuation Assumptions
	The compensation expense related to stock options recognized was determined using the Black-Scholes option valuation model. Option valuation models require the input of subjective assumptions and these assumptions can vary over time. The weighted average assumptions used were as follows:
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Dividend yield		—			—			—			—
	Risk-free interest rate		1.27	%		0.7	%		1.27	%		0.68	%
	Expected volatility		100.47	%		86.21	%		100.68	%		91.48	%
	Forfeiture rate		13.94	%		13.9	%		13.94	%		13.9	%
	Expected term (years)		4.45			4.06			4.45			4.06
	Fair value per share at grant date	$	0.51		$	0.47		$	0.54		$	0.42
	For the three and six months ended June 30, 2014, the volatility assumption was determined by the trading history for the Company. Prior to 2014, the Company did not have sufficient trading history for its common stock and its volatility assumption was determined by examining the historical volatilities for industry peers and the trading history for the Company’s common stock. The Company will continue to use its historical stock price volatility and expected term assumption for future periods. The risk-free interest rate assumption is based on the U.S. Treasury instruments whose term was consistent with the expected term of the Company’s stock options. The expected dividend assumption is based on the Company’s history and expectation of dividend payouts. Different estimates of volatility and expected term could materially change the value of an option and the resulting expense. The expected term of stock options represents the weighted-average period the stock options are expected to remain outstanding and is based on the options vesting terms, contractual terms and historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior.
	Employee Stock-Based Compensation
	The table below presents information related to stock option activity for the six months ended June 30, 2014, as follows:
								Weighted-
								Average
					Weighted-			Remaining
		Number of			Average			Contractual			Aggregate
		Options			Exercise			Term			Intrinsic
		Outstanding			Price			(In years)			Value
	Outstanding at December 31, 2013		9,705,084		$	0.5
	Options granted		1,397,000			0.76
	Options exercised		(310,831	)		0.33
	Options cancelled/forfeited/expired		(836,084	)		1.31
	Outstanding at June 30, 2014		9,955,169		$	0.45			7.57		$	3,532,347
	Exercisable at June 30, 2014		6,261,138		$	0.41			7		$	2,614,186
	Vested and expected to vest at June 30, 2014		9,423,723		$	0.44			7.5		$	3,436,748

Stock_Warrants

Stock Warrants	6 Months Ended
	Jun. 30, 2014
Stock Warrants	'
	12. Stock Warrants
	The Company issues warrants to investors as part of its overall financing strategy and to vendors in order to reduce costs. In connection with the Loan and Security Agreement the Company entered into with Comerica in September 2011 (see Note 8 to these Notes to Condensed Financial Statements), the Company issued a warrant to purchase 480,769 shares of the Company’s common stock, at an exercise price of $0.26 per share and with an expiration date in September 2018. The initial fair value of the warrant was calculated using the Black-Scholes option pricing model and the following assumptions: volatility of 88.03%, risk-free interest rate of 1.36%, exercise price of $0.26 and an expected life of 7 years. The fair value of the warrant was determined to be $94,000 and was recorded as equity in additional paid-in-capital and a discount to the carrying value of the loan. Through August 2012, the discount was amortized to interest expense using the effective interest rate method over the 48-month term of the original loan. Beginning in September 2012 in connection with the First Amended Loan and Security Agreement between the Company and Comerica, and continuing in October 2013 with the Second Amended Loan and Security Agreement between the Company and Comerica (see Note 8 to these Notes to Condensed Financial Statements), the unamortized discounts are being recognized over the remaining term of the amended loan, which matures in December 2016.
	In connection with the First Amended Loan and Security Agreement, the Company issued a warrant to purchase 168,919 shares of the Company’s common stock, at an exercise price of $0.37 per share. This warrant expires in September 2019. The initial fair value of the warrant was calculated using the Black-Scholes option pricing model and the following assumptions: volatility of 89.87%, risk-free interest rate of 1.03%, exercise price of $0.37 and an expected life of 7 years. The fair value of the warrant was determined to be $48,000 and was recorded as equity in additional paid-in-capital and a discount to the carrying value of the loan. The discount is being amortized to interest expense using the effective interest rate method over the remaining term of the amended loan which matures in September 2016.
	In connection with the Second Amended Loan and Security Agreement, the Company issued a warrant to purchase 96,685 shares of the Company’s common stock, at an exercise price of $1.81 per share. This warrant expires in October 2020. The initial fair value of the warrant was calculated using the Black-Scholes option pricing model and the following assumptions: volatility of 89.01%, risk-free interest rate of 2.05%, exercise price of $1.81 and an expected life of 7 years. The fair value of the warrant was determined to be $136,000 and was recorded as equity in additional paid-in-capital and a discount to the carrying value of the loan. The discount is being amortized to interest expense using the effective interest rate method over the remaining term of the amended loan which matures in December 2016.
	In August 2013, the Company issued 386,784 shares of common stock pursuant to a cashless exercise of Comerica’s warrant to purchase 480,769 shares at an exercise price of $0.26 per share. As of June 30, 2014, there were warrants outstanding to purchase 265,604 shares of the Company’s common stock, with a weighted-average exercise price of $0.89 per share and an aggregate exercise price of $0.2 million.
	The following table summarizes information about all warrants outstanding as of June 30, 2014:
		Warrants Outstanding and Exercisable
				Weighted
				Average		Weighted
				Remaining		Average
		Number		Contractual		Exercise
	Exercise Price	Outstanding		Life (In Years)		Price
	$0.37		168,919		5.2	$	0.37
	$1.81		96,685		6.3	$	1.81
			265,604		5.6	$	0.89

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies	'
	13. Commitments and Contingencies
	Lease Commitments
	The Company leases an office and laboratory facility (the “349 Facility”) under a long-term, non-cancelable operating lease agreement, which expires in December 2016.
	In 2010, the Company recorded a lease obligation associated with the 349 Facility, which contained a lease payment that exceeded current market rates. Accordingly, the Company recognized a $4.1 million unfavorable lease obligation, included in the accompanying balance sheet. The Company amortizes the unfavorable lease obligation using the effective interest rate method.
	Rent expense for the Company’s facilities was $460,000 and $925,000 for the three and six months ended June 30, 2014, respectively, and $487,000 and $978,000, respectively, for the same periods in 2013. The terms of the lease for the 349 Facility provides for rental payments on a graduated scale. The Company recognizes rent expense on a straight-line basis over the lease period. Deferred rent of $362,000 and $387,000 at June 30, 2014 and December 31, 2013, respectively, is included in the accompanying balance sheets.
	As of June 30, 2014, future minimum lease payments under non-cancelable operating leases are as follows (in thousands):
		Operating
		Leases
	2014 (remainder of year)	$	1,290
	2015		2,658
	2016		2,738
	Total minimum lease payments	$	6,686
	Research and Development Commitments and Contingencies
	In March 2014, the Company entered into a License and Supply Agreement (the “Agreement”) with B.R.A.H.M.S. GmbH. Under the terms of the Agreement, the Company paid €750,000 in April 2014 and it is obligated to pay another €500,000 in March 2015. The Company may pay up to €600,000 in development and regulatory milestones and post-launch commercial milestones up to a total of €1,000,000.

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Taxes	'
	14. Income Taxes
	Provision for Income Tax
	The Company’s effective tax rate is 0% for income tax for the six months ended June 30, 2014 and the Company expects that its effective tax rate for the full year 2014 will be 0%. Based on the weight of available evidence, including cumulative losses since inception and expected future losses, the Company has determined that it is more likely than not that the deferred tax asset amount will not be realized and therefore a valuation allowance has been provided on net deferred tax assets.
	Under the provisions of Section 382 and 383 of the Internal Revenue Code (the “Code”), a change of control, as defined in the Code, may impose an annual limitation on the amount of the Company’s net operating loss and tax credit carryforwards, and other tax attributes, that can be used to reduce future tax liabilities.
	The Company files U.S. Federal and multiple state tax returns. The Company is currently not subject to any income tax examinations. Due to the Company’s losses, generally all years remain open.
	Uncertain Tax Positions
	Effective January 1, 2009, the Company adopted ASC 740-10, which requires that the Company recognize the financial statement effects of a tax position when it becomes more likely than not, based upon the technical merits, that the position will be sustained upon examination.
	The gross amount of unrecognized tax benefits as of June 30, 2014 is $1.6 million related to the reserve on R&D credits, none of which will affect the effective tax rate if recognized due to the valuation allowance. The Company does not expect any material changes in the next 12 months in unrecognized tax benefits.
	The Company recognizes interest and/or penalties related to uncertain tax positions. To the extent accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected in the period that such determination is made. The interest and penalties are recognized as other expense and not tax expense. The Company currently has no interest and penalties related to uncertain tax positions.

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 30, 2014
Subsequent Events	'
	15. Subsequent Events
	None

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	In July 2013, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2013-11, “Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force).” The amendments in this ASU provide guidance on the financial statements presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability. The amendments in this ASU do not require new recurring disclosures and are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. This ASU has been adopted since the effective date and there was no impact to the financial statements as a result of this adoption.
	In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers” The amendment in this ASU provide guidance on the revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The core principle of this update provides guidance to identify the performance obligations under the contract(s) with a customer and how to allocate the transaction price to the performance obligations in the contract. It further provide guidance to recognize revenue when (or as) the entity satisfies a performance obligation. The Company is evaluating the impact of this standard.
Fair Value Measurements	'
	Fair Value Measurements
	In accordance with FASB’s Accounting Standard Codification (“ASC”) 820, the Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The guidance establishes three levels of the fair value hierarchy as follows:
	Level 1: Observable inputs, such as quoted prices in active markets for identical assets or liabilities;
	Level 2: Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;
	Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
Basic and Diluted Net Loss per Common Share	'
	Basic net loss per common share is based on the weighted average number of common shares outstanding during the period. Diluted net loss per common share is based on the weighted average number of common shares and other dilutive securities outstanding during the period, provided that including these dilutive securities does not increase the net loss per share.

Cash_and_Cash_Equivalents_Tabl

Cash and Cash Equivalents (Tables)	6 Months Ended
	Jun. 30, 2014
Cash and Cash Equivalents	'
	The following is a summary of cash and cash equivalents at June 30, 2014 and December 31, 2013 (in thousands):
		30-Jun-14
				Unrealized		Unrealized		Estimated
		Cost Basis		Gains		Losses		Fair Value
	Cash and cash equivalents:
	Cash	$	6,369	$	—	$	—	$	6,369
	Money market funds		4,047		—		—		4,047
	Total cash and cash equivalents	$	10,416	$	—	$	—	$	10,416
		31-Dec-13
				Unrealized		Unrealized		Estimated
		Cost Basis		Gains		Losses		Fair Value
	Cash and cash equivalents:
	Cash	$	12,800	$	—	$	—	$	12,800
	Money market funds		4,047		—		—		4,047
	Total cash and cash equivalents	$	16,847	$	—	$	—	$	16,847
Fair Value Hierarchy for Financial Assets Measured at Fair Value on Recurring Basis	'
	The following table represents the Company’s fair value hierarchy for its financial assets (cash and cash equivalents) measured at fair value on a recurring basis as of June 30, 2014 and December 31, 2013 (in thousands):
				Fair Value Measurements
				Quoted Prices		Significant
				In Active		other		Significant
		Balance at		Markets for		Observable		Unobservable
		June 30,		Identical Assets		Inputs		Inputs
		2014		Level 1		Level 2		Level 3
	Assets:
	Cash	$	6,369	$	6,369	$	—	$	—
	Money market funds		4,047		4,047		—		—
	Restricted cash		1,400		—		1,400		—
		$	11,816	$	10,416	$	1,400	$	—
				Fair Value Measurements
				Quoted Prices		Significant
				In Active		other		Significant
		Balance at		Markets for		Observable		Unobservable
		December 31,		Identical Assets		Inputs		Inputs
		2013		Level 1		Level 2		Level 3
	Assets:
	Cash	$	12,800	$	12,800	$	—	$	—
	Money market funds		4,047		4,047		—		—
	Restricted cash		1,400		—		1,400		—
		$	18,247	$	16,847	$	1,400	$	—

Inventory_Tables

Inventory (Tables)	6 Months Ended
	Jun. 30, 2014
Inventory	'
	Inventory consists of the following (in thousands):
		June 30,			December 31,
		2014			2013
	Finished goods	$	219	$	361
	Raw materials		134		99
		$	353	$	460

Property_Plant_and_Equipment_T

Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2014
Schedule of Estimated Useful Lives for Significant Property and Equipment	'
	The estimated useful lives for significant property and equipment categories are as follows:
	Office and laboratory equipment	3 years
	Computer equipment and software	3 years
	Leasehold improvements	Term of lease agreement
Property and Equipment at Cost Less Accumulated Depreciation	'
	The following is a summary of property and equipment at cost less accumulated depreciation as of June 30, 2014 and December 31, 2013 (in thousands):
		June 30,			December 31,
		2014			2013
	Laboratory equipment	$	2,403		$	2,299
	Leasehold improvements		616			616
	Computer and software		332			299
	Furniture and fixtures		81			81
	Construction in progress		48			149
			3,480			3,444
	Less: Accumulated depreciation and amortization		(2,638	)		(2,476	)
		$	842		$	968

Total_Accrued_and_Other_Curren1

Total Accrued and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2014
Schedule of Total Accrued and Other Current Liabilities	'
	Total accrued and other current liabilities include the following as of June 30, 2014 and December 31, 2013 (in thousands):
		June 30,		December 31,
		2014		2013
	Accrued payroll and related expense	$	1,067	$	1,481
	Accrued research obligations		817		46
	Accrued consulting expense		174		207
	Accrued inventory		125		—
	Accrued travel and entertainment		88		53
	Accrued sales and excise tax		73		71
	Accrued legal and patent expense		67		124
	Accrued royalty expense		65		65
	Accrued property and equipment		—		11
	Other current liabilities		190		145
	Total accrued and other current liabilities	$	2,666	$	2,203

Concentration_of_Credit_Risk_T

Concentration of Credit Risk (Tables)	6 Months Ended
	Jun. 30, 2014
Revenues from Customers	'
	Revenues from the following customers represented a significant portion of total revenue for the three and six months ended June 30, 2014 and 2013 and accounts receivable as of June 30, 2014 and December 31, 2013:
		Revenue						Revenue						Accounts Receivable
		Three Months Ended						Six Months Ended
		June 30,						June 30,						June 30,			December 31,
		2014			2013			2014			2013			2014			2013
	Customer A		34	%		41	%		32	%		44	%		28	%		36	%
	Customer B		15	%		14	%		15	%		13	%		15	%		11	%
	Customer C		13	%		5	%		11	%		4	%		24	%		3	%
	Customer D		13	%		9	%		14	%		9	%		7	%		10	%
	Customer E		5	%		6	%		4	%		6	%		6	%		15	%
	Total		80	%		75	%		76	%		76	%		80	%		75	%

Notes_Payable_Tables

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2014
Future Minimum Payments for Notes Payable	'
	As of June 30, 2014, future minimum payments for the notes payable are as follows (in thousands):
	2014 (remainder of year)	$	1,686
	2015		3,233
	2016		4,728
	Total minimum payments		9,647
	Less: Amount representing interest		(1,075	)
	Present value of minimum payments		8,572
	Less: Unamortized debt discount		(140	)
	Notes payable, net		8,432
	Less: Notes payable, current portion		2,778
	Non-current portion of notes payable	$	5,654

Basic_and_Diluted_Net_Loss_per1

Basic and Diluted Net Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2014
Outstanding Securities Considered Anti-Dilutive, and Therefore Excluded from Computation of Diluted Net Loss Per Share	'
	The effect of the options and warrants was anti-dilutive for the six months ended June 30, 2014 and 2013. The following table shows the total outstanding securities considered anti-dilutive and therefore, excluded from the computation of diluted net loss per share (in thousands):
		As of
		June 30,
		2014		2013
	Options to purchase common stock		9,955		9,078
	Warrants to purchase common stock		266		650
	Restricted stock units		42		—
	Total		10,263		9,728

Stock_Based_Compensation_Table

Stock Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2014
Summary of Nonvested Restricted Stock Units	'
	A summary for the six months ended June 30, 2014 is as follows:
								Weighted
					Average			Remaining
					Grant Date			Vesting			Aggregate
		Shares of			Fair Value			Period			Intrinsic
		Underlying RSUs			Per Share			(In years)			Value
	Nonvested at December 31, 2013		41,708		$	1.33
	Options exercised		—			—
	Options cancelled/forfeited/expired		—			—
	Nonvested at June 30, 2014		41,708		$	1.33			—		$	30,864
Summary of Stock Compensation Expense Related to Employee Stock Options and Employee Stock Based Compensation	'
	The following table summarizes stock compensation expense related to employee stock options and employee stock-based compensation for the three and six months ended June 30, 2014 and 2013, which was incurred as follows (in thousands):
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Stock-based compensation expense:
	General and administrative	$	139		$	57		$	263		$	117
	Research and development		(30	)		30			13			54
	Sales and marketing		31			32			63			58
	Product costs		7			6			12			10
	Total stock-based compensation expense	$	147		$	125		$	351		$	239
Weighted Average Assumptions Used with Regard to Stock Option	'
	The weighted average assumptions used were as follows:
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Dividend yield		—			—			—			—
	Risk-free interest rate		1.27	%		0.7	%		1.27	%		0.68	%
	Expected volatility		100.47	%		86.21	%		100.68	%		91.48	%
	Forfeiture rate		13.94	%		13.9	%		13.94	%		13.9	%
	Expected term (years)		4.45			4.06			4.45			4.06
	Fair value per share at grant date	$	0.51		$	0.47		$	0.54		$	0.42
Schedule of Stock Option Activity	'
	The table below presents information related to stock option activity for the six months ended June 30, 2014, as follows:
								Weighted-
								Average
					Weighted-			Remaining
		Number of			Average			Contractual			Aggregate
		Options			Exercise			Term			Intrinsic
		Outstanding			Price			(In years)			Value
	Outstanding at December 31, 2013		9,705,084		$	0.5
	Options granted		1,397,000			0.76
	Options exercised		(310,831	)		0.33
	Options cancelled/forfeited/expired		(836,084	)		1.31
	Outstanding at June 30, 2014		9,955,169		$	0.45			7.57		$	3,532,347
	Exercisable at June 30, 2014		6,261,138		$	0.41			7		$	2,614,186
	Vested and expected to vest at June 30, 2014		9,423,723		$	0.44			7.5		$	3,436,748

Stock_Warrants_Tables

Stock Warrants (Tables)	6 Months Ended
	Jun. 30, 2014
Summarized Information about All Warrants Outstanding	'
	The following table summarizes information about all warrants outstanding as of June 30, 2014:
		Warrants Outstanding and Exercisable
				Weighted
				Average		Weighted
				Remaining		Average
		Number		Contractual		Exercise
	Exercise Price	Outstanding		Life (In Years)		Price
	$0.37		168,919		5.2	$	0.37
	$1.81		96,685		6.3	$	1.81
			265,604		5.6	$	0.89

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2014
Future Minimum Lease Payments Under Non-Cancelable Operating Leases	'
	As of June 30, 2014, future minimum lease payments under non-cancelable operating leases are as follows (in thousands):
		Operating
		Leases
	2014 (remainder of year)	$	1,290
	2015		2,658
	2016		2,738
	Total minimum lease payments	$	6,686

Business_Overview_Additional_I

Business Overview - Additional Information (Detail) (USD $)	6 Months Ended	12 Months Ended	3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended
	Jun. 30, 2014	Dec. 31, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
		Lives	Product Revenue	Product Revenue	Product Revenue	Product Revenue	Product Costs	Product Costs	Product Costs	Product Costs
Schedule Of Description Of Business [Line Items]	'	'	'	'	'	'	'	'	'	'
Liquidity ratio	1.25	'	'	'	'	'	'	'	'	'
Cumulative net loss	$6,000,000	'	'	'	'	'	'	'	'	'
Cumulative net loss under the covenant	5,100,000	'	'	'	'	'	'	'	'	'
Addressable United States market for tests	'	36,000,000	'	'	'	'	'	'	'	'
Excise tax	'	'	$98,000	$109,000	$171,000	$214,000	$110,000	$132,000	$193,000	$253,000

Cash_and_Cash_Equivalents_Cash

Cash and Cash Equivalents - Cash and Cash Equivalents (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Cash And Cash Equivalents [Line Items]	'	'	'	'
Cash and cash equivalents, Cost Basis	$10,416	$16,847	$11,970	$12,851
Cash and cash equivalents, Unrealized Gains	'	'	'	'
Cash and cash equivalents, Unrealized Losses	'	'	'	'
Cash and cash equivalents, Estimated Fair Value	10,416	16,847	'	'
Cash [Member]	'	'	'	'
Cash And Cash Equivalents [Line Items]	'	'	'	'
Cash and cash equivalents, Cost Basis	6,369	12,800	'	'
Cash and cash equivalents, Unrealized Gains	'	'	'	'
Cash and cash equivalents, Unrealized Losses	'	'	'	'
Cash and cash equivalents, Estimated Fair Value	6,369	12,800	'	'
Money market funds [Member]	'	'	'	'
Cash And Cash Equivalents [Line Items]	'	'	'	'
Cash and cash equivalents, Cost Basis	4,047	4,047	'	'
Cash and cash equivalents, Unrealized Gains	'	'	'	'
Cash and cash equivalents, Unrealized Losses	'	'	'	'
Cash and cash equivalents, Estimated Fair Value	$4,047	$4,047	'	'

Cash_and_Cash_Equivalents_Fair

Cash and Cash Equivalents - Fair Value Hierarchy for Financial Assets Measured at Fair Value on Recurring Basis (Detail) (Fair value, measurements, recurring [Member], USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Assets, Fair Value Measurements	$11,816	$18,247
Restricted cash [Member]	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Assets, Fair Value Measurements	1,400	1,400
Quoted Prices In Active Markets for Identical Assets (Level 1) [Member]	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Assets, Fair Value Measurements	10,416	16,847
Significant other Observable Inputs (Level 2) [Member]	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Assets, Fair Value Measurements	1,400	1,400
Significant other Observable Inputs (Level 2) [Member] | Restricted cash [Member]	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Assets, Fair Value Measurements	1,400	1,400
Significant Unobservable Inputs (Level 3) [Member]	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Assets, Fair Value Measurements	'	'
Significant Unobservable Inputs (Level 3) [Member] | Restricted cash [Member]	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Assets, Fair Value Measurements	'	'
Cash [Member]	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Assets, Fair Value Measurements	6,369	12,800
Cash [Member] | Quoted Prices In Active Markets for Identical Assets (Level 1) [Member]	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Assets, Fair Value Measurements	6,369	12,800
Cash [Member] | Significant Unobservable Inputs (Level 3) [Member]	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Assets, Fair Value Measurements	'	'
Money market funds [Member]	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Assets, Fair Value Measurements	4,047	4,047
Money market funds [Member] | Quoted Prices In Active Markets for Identical Assets (Level 1) [Member]	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Assets, Fair Value Measurements	4,047	4,047
Money market funds [Member] | Significant Unobservable Inputs (Level 3) [Member]	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Assets, Fair Value Measurements	'	'

Cash_and_Cash_Equivalents_Addi

Cash and Cash Equivalents - Additional Information (Detail) (USD $)	Jun. 30, 2014
In Millions, unless otherwise specified
Cash And Cash Equivalents [Line Items]	'
Notes payable face value	$8.60

Inventory_Inventory_Detail

Inventory - Inventory (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory [Line Items]	'	'
Finished goods	$219	$361
Raw materials	134	99
Total inventory	$353	$460

Property_Plant_and_Equipment_S

Property, Plant and Equipment - Schedule of Estimated Useful Lives for Significant Property and Equipment (Detail)	6 Months Ended
	Jun. 30, 2014
Office and laboratory equipment [Member]	'
Property Plant And Equipment [Line Items]	'
Estimated useful lives	'3 years
Computer equipment and software [Member]	'
Property Plant And Equipment [Line Items]	'
Estimated useful lives	'3 years
Leasehold improvements [Member]	'
Property Plant And Equipment [Line Items]	'
Leasehold improvements	'Term of lease agreement

Property_Plant_and_Equipment_P

Property, Plant and Equipment - Property and Equipment at Cost Less Accumulated Depreciation (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property Plant And Equipment [Line Items]	'	'
Gross property and equipment	$3,480	$3,444
Less: Accumulated depreciation and amortization	-2,638	-2,476
Total Property, Plant and Equipment	842	968
Laboratory equipment [Member]	'	'
Property Plant And Equipment [Line Items]	'	'
Gross property and equipment	2,403	2,299
Leasehold improvements [Member]	'	'
Property Plant And Equipment [Line Items]	'	'
Gross property and equipment	616	616
Computer equipment and software [Member]	'	'
Property Plant And Equipment [Line Items]	'	'
Gross property and equipment	332	299
Furniture and fixtures [Member]	'	'
Property Plant And Equipment [Line Items]	'	'
Gross property and equipment	81	81
Construction in progress [Member]	'	'
Property Plant And Equipment [Line Items]	'	'
Gross property and equipment	$48	$149

Property_Plant_and_Equipment_A

Property, Plant and Equipment - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Property Plant And Equipment [Line Items]	'	'	'	'
Depreciation and amortization expense	$141,000	$136,000	$280,000	$266,000

Total_Accrued_and_Other_Curren2

Total Accrued and Other Current Liabilities - Schedule of Total Accrued and Other Current Liabilities (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Expenses And Other Liabilities [Line Items]	'	'
Accrued payroll and related expense	$1,067	$1,481
Accrued research obligations	817	46
Accrued consulting expense	174	207
Accrued inventory	125	'
Accrued travel and entertainment	88	53
Accrued sales and excise tax	73	71
Accrued legal and patent expense	67	124
Accrued royalty expense	65	65
Accrued property and equipment	'	11
Other current liabilities	190	145
Total accrued and other current liabilities	$2,666	$2,203

Total_Accrued_and_Other_Curren3

Total Accrued and Other Current Liabilities - Additional Information (Detail) (Thermo Fisher Scientific [Member], License and Supply Agreement [Member], USD $)	Jun. 30, 2014
In Millions, unless otherwise specified
Thermo Fisher Scientific [Member] | License and Supply Agreement [Member]	'
Accrued Expenses And Other Liabilities [Line Items]	'
Accrued research obligations	$0.70

Concentration_of_Credit_Risk_R

Concentration of Credit Risk - Revenues from Customers (Detail)

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Credit Concentration Risk [Member]

Credit Concentration Risk [Member]

Credit Concentration Risk [Member]

Credit Concentration Risk [Member]

Credit Concentration Risk [Member]

Credit Concentration Risk [Member]

Credit Concentration Risk [Member]

Credit Concentration Risk [Member]

Credit Concentration Risk [Member]

Credit Concentration Risk [Member]

Credit Concentration Risk [Member]

Credit Concentration Risk [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Revenue [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Accounts Receivable [Member]

Customer A [Member]

Customer A [Member]

Customer A [Member]

Customer A [Member]

Customer B [Member]

Customer B [Member]

Customer B [Member]

Customer B [Member]

Customer C [Member]

Customer C [Member]

Customer C [Member]

Customer C [Member]

Customer D [Member]

Customer D [Member]

Customer D [Member]

Customer D [Member]

Customer E [Member]

Customer E [Member]

Customer E [Member]

Customer E [Member]

Customer A [Member]

Customer A [Member]

Customer B [Member]

Customer B [Member]

Customer C [Member]

Customer C [Member]

Customer D [Member]

Customer D [Member]

Customer E [Member]

Customer E [Member]

Concentration Risk [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Revenue and Accounts Receivable

80.00%

75.00%

76.00%

76.00%

34.00%

41.00%

32.00%

44.00%

15.00%

14.00%

15.00%

13.00%

13.00%

5.00%

11.00%

4.00%

13.00%

9.00%

14.00%

9.00%

5.00%

6.00%

4.00%

6.00%

80.00%

75.00%

28.00%

36.00%

15.00%

11.00%

24.00%

3.00%

7.00%

10.00%

6.00%

15.00%

Notes_Payable_Additional_Infor

Notes Payable - Additional Information (Detail) (USD $)	1 Months Ended		6 Months Ended		6 Months Ended		12 Months Ended	6 Months Ended		0 Months Ended
	Aug. 31, 2013	Sep. 30, 2011	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Jun. 30, 2014	Oct. 17, 2013	Jun. 30, 2014	Jun. 30, 2014	Sep. 30, 2011
			Installment		First Amended Loan and Security Agreement [Member]	Second Amended Loan and Security Agreement [Member]	Second Amended Loan and Security Agreement [Member]	Minimum [Member]	Maximum [Member]	Notes payable [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'	'
Proceeds from bank debt	'	'	'	'	'	'	'	'	'	$5,000,000
Interest rate on loan	'	'	'	'	'	'	'	'	'	5.25%
Period for monthly installment	'	'	'monthly	'	'	'	'	'	'	'
Debt instrument number of installments	'	'	36	'	'	'	'	'	'	'
Loan processing fee	'	'	25,000	'	'	'	'	'	'	'
Additional fee required	'	'	100,000	'	'	'	'	'	'	'
Advance notice period to the bank	'	'	'30 days	'	'	'	'	'	'	'
Warrant issued to purchase common stock	480,769	480,769	'	'	'	'	'	'	'	'
Liquidity ratio	'	'	'	'	'	'	'	1.25	'	'
Cumulative net loss	'	'	-204,437,000	-199,896,000	'	'	'	'	6,000,000	'
Repayment of term loan description	'	'	'The repayment of the term loan may be accelerated, at the option of Comerica, following the occurrence of an event of default, which would require the Company to pay to Comerica an amount equal to the sum of: (i) all outstanding principal plus accrued interest, (ii) the final payment, plus (iii) all other sums, that shall have become due and payable but have not been paid, including interest at the default rate with respect to any past due amounts. As of June 30, 2014, the Company was in compliance with all the covenants including having a cumulative net loss of $5.1 million as of June 30, 2014	'	'	'	'	'	'	'
Cumulative net loss	'	'	5,100,000	'	'	'	'	'	'	'
Extended interest-only payment period	'	'	'	'	23-Sep-13	31-Dec-13	'	'	'	'
Amended and restated loan and security, maturity date	'	'	'	'	23-Sep-16	1-Dec-16	'	'	'	'
Monthly principal payments by amortizing the loan	'	'	'	'	'48 months	'42 months	'	'	'	'
Amendment access fee	'	'	'	'	50,000	50,000	'	'	'	'
Common stock purchase	'	'	'	'	168,919	96,685	'	'	'	'
Warrants exercise price per share	'	'	'	'	$0.37	$1.81	'	'	'	'
Warrant expiry date	'	'	'	'	11-Sep-19	17-Oct-20	'	'	'	'
Present value of modified debt instrument	'	'	'	'	10.00%	'	'	'	'	'
Debt discount	'	'	'	'	48,000	136,000	'	'	'	'
Unamortized debt discount	'	'	140,000	'	72,000	77,000	'	'	'	'
Increase in aggregate principal amount	'	'	'	'	'	'	5,000,000	'	'	'
Outstanding principal amount	'	'	$8,572,000	'	'	'	$10,000,000	'	'	'
Interest rate on loan	'	'	'	'	'	'	6.45%	'	'	'

Notes_Payable_Future_Minimum_P

Notes Payable - Future Minimum Payments for Notes Payable (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Notes Payable [Abstract]	'	'
2014 (remainder of year)	$1,686	'
2015	3,233	'
2016	4,728	'
Total minimum payments	9,647	'
Less: Amount representing interest	-1,075	'
Outstanding principal amount	8,572	'
Less: Unamortized debt discount	-140	'
Notes payable, net	8,432	'
Less: Notes payable, current portion	2,778	2,763
Non-current portion of notes payable	$5,654	$7,047

Common_Stock_Additional_Inform

Common Stock - Additional Information (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Class Of Stock [Line Items]	'	'
Common stock, shares authorized	100,000,000	100,000,000
Increase in number of authorized shares of common stock, par value	$0.01	$0.01

Basic_and_Diluted_Net_Loss_per2

Basic and Diluted Net Loss per Share - Outstanding Securities Considered Anti-Dilutive, and Therefore Excluded from Computation of Diluted Net Loss Per Share (Detail)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]	'	'
Total	10,263	9,728
Options to purchase common stock [Member]	'	'
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]	'	'
Total	9,955	9,078
Warrants to purchase common stock [Member]	'	'
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]	'	'
Total	266	650
Restricted stock units [Member]	'	'
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]	'	'
Total	42	'

Stock_Based_Compensation_Addit

Stock Based Compensation - Additional Information (Detail) (USD $)

6 Months Ended

6 Months Ended

6 Months Ended

1 Months Ended

0 Months Ended

6 Months Ended

1 Months Ended

1 Months Ended

0 Months Ended

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

17-May-12

17-May-12

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Oct. 31, 2004

Jun. 30, 2014

Aug. 06, 2013

Jun. 30, 2014

Sep. 30, 2011

Jun. 30, 2014

Oct. 31, 2011

Jun. 30, 2014

Feb. 01, 2012

Jun. 30, 2014

2012 Equity Incentive Award Plan [Member]

1996 Stock Option Plan [Member]

1996 Stock Option Plan [Member]

1998 Director Stock Option Plan [Member]

Restricted stock units [Member]

Restricted stock units [Member]

Options to purchase common stock [Member]

Options to purchase common stock [Member]

Options to purchase common stock [Member]

Options to purchase common stock [Member]

Director [Member]

Director [Member]

Director [Member]

Director [Member]

Chief Executive Officer [Member]

Chief Executive Officer [Member]

Chief Business Officer [Member]

Chief Business Officer [Member]

Chief Financial Officer [Member]

Chief Financial Officer [Member]

2012 Equity Incentive Award Plan [Member]

Amendment 2012 Equity Incentive Award Plan [Member]

1996 Stock Option Plan [Member]

1998 Director Stock Option Plan [Member]

Non-Plan Grants [Member]

Non-Plan Grants [Member]

Restricted stock units [Member]

Restricted stock units [Member]

Non-Plan Grants [Member]

Non-Plan Grants [Member]

Non-Plan Grants [Member]

Non-Plan Grants [Member]

Non-Plan Grants [Member]

Non-Plan Grants [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of common stock authorized for issuance

'

'

'

'

'

'

'

'

3,000,000

4,000,000

4,750,000

300,000

'

'

'

'

'

'

'

'

'

'

Issuable upon exercise of options vest

'

'

'4 years

'

'

'

'

'

'

'

'4 years

'

'

'

'

'

'

'

'

'

'

'

Non Employee Stock Options Vesting Period

'1 year

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options outstanding

9,955,169

9,705,084

3,477,674

2,843,685

6,398,904

170,000

'

'

'

'

'

'

'

30,000

'

'

'

1,530,000

'

1,018,458

'

1,055,352

Shares available for grant

'

'

5,784,701

'

'

'

'

'

'

'

'

'

30,000

'

'

'

1,530,000

'

1,130,000

'

1,060,000

'

Condition for stock option expiry

'Option terms expire no later than 10 years from the date of grant, or 5 years from the date the option is granted to a greater than 10% stockholder.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Condition for stock options exercisable

'The stock options are exercisable at not less than the fair market value of the stock at the date of grant, or not less than 110% of the fair market value of the stock at the date of grant if granted to a greater than 10% stockholder.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted Stock Units awarded, outstanding

'

'

'

'

'

'

41,708

41,708

'

'

'

'

'

'

'

41,708

'

'

'

'

'

'

Percentage increased by the number of issued and outstanding common stock

'

'

'

'

'

'

'

'

'

'

3.50%

'

'

'

'

'

'

'

'

'

'

'

Options expire from the date of grant

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

Period between grant date and vesting period start date

'

'

'

'

'

'

'

'

'

'

'1 year

'

'

'

'

'

'

'

'

'

'

'

Determination of Non qualified stock options exercise price fair market value of stock minimum percentage

'

'

'

85.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares transferred form prior plans available for issuance under the plan

'

'

'

'

1,555,492

130,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock option plans, exercise price per share

$0.33

'

'

'

'

'

'

'

'

'

'

'

$12.27

'

'

'

$0.25

'

$0.26

'

$0.28

'

Restricted Stock Units awarded to directors

'

'

'

'

'

'

'

'

'

'

'

'

'

'

41,708

'

'

'

'

'

'

'

Restricted Stock Units, grant-date fair value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$55,000

'

'

'

'

'

'

'

RSU entitles the recipient to receive share of the Company's common stock upon vesting

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1

'

'

'

'

'

'

Restricted Stock Units, vested

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

Stock-based compensation, total remaining unrecognized expense

$979,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock-based compensation expenses recognition period

'2 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock_Based_Compensation_Summa

Stock Based Compensation - Summary of Nonvested Restricted Stock Units (Detail) (Restricted stock units [Member], USD $)	6 Months Ended
In Thousands, except Share data, unless otherwise specified	Jun. 30, 2014
Restricted stock units [Member]	'
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'
Shares of Underlying RSUs, Nonvested, Beginning balance	41,708
Shares of Underlying RSUs, Options exercised	'
Shares of Underlying RSUs, Options cancelled/forfeited/expired	'
Shares of Underlying RSUs, Nonvested, Ending balance	41,708
Average Grant Date Fair Value Per Share, Nonvested, Beginning balance	$1.33
Average Grant Date Fair Value Per Share, Options exercised	'
Average Grant Date Fair Value Per Share, Options cancelled/forfeited/expired	'
Average Grant Date Fair Value Per Share, Nonvested, Ending balance	$1.33
Weighted Remaining Vesting Period, Nonvested, Ending balance	'0 years
Aggregate Intrinsic Value	$30,864

Stock_Based_Compensation_Summa1

Stock Based Compensation - Summary of Stock Compensation Expense Related to Employee Stock Options and Employee Stock Based Compensation (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Stock-based compensation expense:	'	'	'	'
Stock-based compensation	$147	$125	$351	$239
General and administrative [Member]	'	'	'	'
Stock-based compensation expense:	'	'	'	'
Stock-based compensation	139	57	263	117
Research and development [Member]	'	'	'	'
Stock-based compensation expense:	'	'	'	'
Stock-based compensation	-30	30	13	54
Sales and marketing [Member]	'	'	'	'
Stock-based compensation expense:	'	'	'	'
Stock-based compensation	31	32	63	58
Product costs [Member]	'	'	'	'
Stock-based compensation expense:	'	'	'	'
Stock-based compensation	$7	$6	$12	$10

Stock_Based_Compensation_Weigh

Stock Based Compensation - Weighted Average Assumptions Used with Regard to Stock Option (Detail) (USD $)	1 Months Ended	3 Months Ended		6 Months Ended
	Sep. 30, 2011	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'	'	'	'	'
Dividend yield	'	'	'	'	'
Risk-free interest rate	1.36%	1.27%	0.70%	1.27%	0.68%
Expected volatility	88.03%	100.47%	86.21%	100.68%	91.48%
Forfeiture rate	'	13.94%	13.90%	13.94%	13.90%
Expected term (years)	'	'4 years 5 months 12 days	'4 years 22 days	'4 years 5 months 12 days	'4 years 22 days
Fair value per share at grant date	'	$0.51	$0.47	$0.54	$0.42

Stock_Based_Compensation_Sched

Stock Based Compensation - Schedule of Stock Option Activity (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Number of Options Outstanding, Beginning balance	9,705,084
Number of Options Outstanding, Options granted	1,397,000
Number of Options Outstanding, Options exercised	-310,831
Number of Options Outstanding, Options cancelled/forfeited/expired	-836,084
Number of Options Outstanding, Ending balance	9,955,169
Number of Options Outstanding, Exercisable, Ending balance	6,261,138
Number of Options Outstanding, Vested and expected to vest, Ending balance	9,423,723
Weighted-Average Exercise Price, Outstanding Beginning balance	$0.50
Weighted-Average Exercise Price, Options granted	$0.76
Weighted-Average Exercise Price, Options exercised	$0.33
Weighted-Average Exercise Price, Options cancelled/forfeited/expired	$1.31
Weighted-Average Exercise Price, Outstanding Ending balance	$0.45
Weighted-Average Exercise Price, Exercisable, Ending balance	$0.41
Weighted-Average Exercise Price, Vested and expected to vest, Ending balance	$0.44
Weighted-Average Remaining Contractual Term, Outstanding, Ending balance	'7 years 6 months 26 days
Weighted-Average Remaining Contractual Term, Exercisable, Ending balance	'7 years
Weighted-Average Remaining Contractual Term, Vested and expected to vest, Ending balance	'7 years 6 months
Aggregate Intrinsic Value, Outstanding, Ending balance	$3,532,347
Aggregate Intrinsic Value, Exercisable, Ending balance	2,614,186
Aggregate Intrinsic Value, Vested and expected to vest, Ending balance	$3,436,748

Stock_Warrants_Additional_Info

Stock Warrants - Additional Information (Detail) (USD $)	1 Months Ended		3 Months Ended		6 Months Ended
	Aug. 31, 2013	Sep. 30, 2011	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Class Of Warrant Or Right [Line Items]	'	'	'	'	'	'
Warrant issued to purchase common stock	480,769	480,769	'	'	'	'
Warrants Outstanding and Exercisable, Weighted Average Exercise Price	'	0.26	0.89	'	0.89	'
Volatility	'	88.03%	100.47%	86.21%	100.68%	91.48%
Risk-free interest rate	'	1.36%	1.27%	0.70%	1.27%	0.68%
Expected life of warrant	'	'7 years	'	'	'	'
Fair value of warrant	'	$94,000	'	'	'	'
Discount being amortized to interest expense	'	'48 months	'	'	'	'
Warrant expiry date	'	'2018-09	'	'	'	'
Exercise price of warrant	$0.26	'	'	'	'	'
Common stock issued	386,784	'	'	'	'	'
Warrants Outstanding and Exercisable, Number	'	'	265,604	'	265,604	'
Aggregate exercise price	'	'	'	'	200,000	'
Warrant 0.37 [Member]	'	'	'	'	'	'
Class Of Warrant Or Right [Line Items]	'	'	'	'	'	'
Warrants Outstanding and Exercisable, Weighted Average Exercise Price	'	'	0.37	'	0.37	'
Warrants Outstanding and Exercisable, Number	'	'	168,919	'	168,919	'
Warrant 0.37 [Member] | First Amended Loan and Security Agreement [Member]	'	'	'	'	'	'
Class Of Warrant Or Right [Line Items]	'	'	'	'	'	'
Warrant issued to purchase common stock	'	'	'	'	168,919	'
Warrants Outstanding and Exercisable, Weighted Average Exercise Price	'	'	0.37	'	0.37	'
Volatility	'	'	'	'	89.87%	'
Risk-free interest rate	'	'	'	'	1.03%	'
Expected life of warrant	'	'	'	'	'7 years	'
Fair value of warrant	'	'	'	'	48,000	'
Warrant expiry date	'	'	'	'	'2019-09	'
Loan, maturity date	'	'	'	'	30-Sep-16	'
Warrant 1.81 [Member]	'	'	'	'	'	'
Class Of Warrant Or Right [Line Items]	'	'	'	'	'	'
Warrants Outstanding and Exercisable, Weighted Average Exercise Price	'	'	1.81	'	1.81	'
Warrants Outstanding and Exercisable, Number	'	'	96,685	'	96,685	'
Warrant 1.81 [Member] | Second Amended Loan and Security Agreement [Member]	'	'	'	'	'	'
Class Of Warrant Or Right [Line Items]	'	'	'	'	'	'
Warrant issued to purchase common stock	'	'	'	'	96,685	'
Volatility	'	'	'	'	89.01%	'
Risk-free interest rate	'	'	'	'	2.05%	'
Expected life of warrant	'	'	'	'	'7 years	'
Fair value of warrant	'	'	'	'	$136,000	'
Warrant expiry date	'	'	'	'	'2020-10	'
Exercise price of warrant	'	'	'	'	$1.81	'
Amended and Restated Loan and Security Agreement [Member]	'	'	'	'	'	'
Class Of Warrant Or Right [Line Items]	'	'	'	'	'	'
Loan, maturity date	'	31-Dec-16	'	'	'	'

Stock_Warrants_Summarized_Info

Stock Warrants - Summarized Information about All Warrants Outstanding (Detail)	6 Months Ended
	Jun. 30, 2014	Sep. 30, 2011
Class Of Warrant Or Right [Line Items]	'	'
Warrants Outstanding and Exercisable, Number	265,604	'
Warrants Outstanding and Exercisable, Weighted Average Remaining Contractual Life (In Years)	'5 years 7 months 6 days	'
Warrants Outstanding and Exercisable, Weighted Average Exercise Price	0.89	0.26
Warrant 0.37 [Member]	'	'
Class Of Warrant Or Right [Line Items]	'	'
Warrants Outstanding and Exercisable, Number	168,919	'
Warrants Outstanding and Exercisable, Weighted Average Remaining Contractual Life (In Years)	'5 years 2 months 12 days	'
Warrants Outstanding and Exercisable, Weighted Average Exercise Price	0.37	'
Warrant 1.81 [Member]	'	'
Class Of Warrant Or Right [Line Items]	'	'
Warrants Outstanding and Exercisable, Number	96,685	'
Warrants Outstanding and Exercisable, Weighted Average Remaining Contractual Life (In Years)	'6 years 3 months 18 days	'
Warrants Outstanding and Exercisable, Weighted Average Exercise Price	1.81	'

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail)	3 Months Ended		6 Months Ended			1 Months Ended		3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Apr. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Mar. 31, 2014	Jun. 30, 2014	Dec. 31, 2010
	USD ($)	USD ($)	USD ($)	USD ($)	USD ($)	License and Supply Agreement [Member]	License and Supply Agreement [Member]	License and Supply Agreement [Member]	License and Supply Agreement [Member]	349 Facility [Member]	349 Facility [Member]
						EUR (€)	EUR (€)	Development and regulatory milestones [Member]	Post-launch commercial milestones [Member]		USD ($)
								Potential [Member]	Potential [Member]
								Maximum [Member]	Maximum [Member]
								EUR (€)	EUR (€)
Commitments Contingencies And Litigation [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Lease expiration date	'	'	'	'	'	'	'	'	'	'2016-12	'
Unfavorable lease obligation expense	'	'	'	'	'	'	'	'	'	'	$4,100,000
Rent expense	460,000	487,000	925,000	978,000	'	'	'	'	'	'	'
Deferred rent	362,000	'	362,000	'	387,000	'	'	'	'	'	'
Payment under License and Supply Agreement	'	'	'	'	'	750,000	'	600,000	1,000,000	'	'
Upfront milestone to be settled	'	'	'	'	'	'	€ 500,000	'	'	'	'

Commitments_and_Contingencies_2

Commitments and Contingencies - Future Minimum Lease Payments under Non-Cancelable Operating Leases (Detail) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Commitments Contingencies And Litigation [Line Items]	'
2014 (remainder of year)	$1,290
2015	2,658
2016	2,738
Total minimum lease payments	$6,686

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Effective tax rate	0.00%
Expected effective tax rate current year	0.00%
Unrecognized tax benefits	$1,600,000
Expected material changes in the next 12 months in unrecognized tax benefits	0
Accrued interest and penalties related to uncertain tax positions	$0